Last updated: February 17, 2026
What is the drug associated with NDC 00121-2232?
The National Drug Code (NDC) 00121-2232 corresponds to Eliquis (apixaban), an oral anticoagulant used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is also prescribed for the treatment and prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE).
How does the market landscape for Eliquis compare to competitors?
Market position:
- Eliquis, marketed by Bristol-Myers Squibb and Pfizer, has a leading share among direct oral anticoagulants (DOACs).
- It competes primarily with warfarin, Xarelto (rivaroxaban), and Savaysa (edoxaban).
- In 2022, Eliquis held approximately 35% of the oral anticoagulant market in the U.S., with Xarelto close behind at 29% [1].
Market size:
- The global anticoagulant market was valued at USD 7.6 billion in 2022.
- Expected compound annual growth rate (CAGR) of 7.2% from 2023 to 2030, driven by aging populations and increasing incidence of atrial fibrillation and venous thromboembolism [2].
Key markets:
| Region |
Revenue Share (2022) |
CAGR (2023-2030) |
Notes |
| U.S. |
~50% |
6.8% |
Largest market |
| Europe |
~25% |
7.5% |
Strong adoption |
| Asia-Pacific |
15% |
9.2% |
Growing prescriptions |
| Rest of World |
10% |
7.0% |
Emerging markets |
What are the pricing trends for Eliquis?
Current prices:
- Average wholesale price (AWP) per 60 mg tablet ranges from USD 10.00 to USD 12.50.
- Typical treatment courses cost approximately USD 300 to USD 500 monthly, depending on dosage and insurance coverage.
Price trends over time:
- Prices have remained relatively stable since initial patent expiration in 2026.
- Price erosion is expected to accelerate with increased generic availability, projected to begin in 2028.
- Pre-patent expiration, branded Eliquis was priced at USD 500-USD 600 monthly.
Impact of biosimilars and generics:
- Patent cliff to introduce generics around 2028 could reduce prices by 40–60%, similar to Xarelto and Pradaxa trends.
- Entry of biosimilars or enhanced formulations could further influence pricing dynamics.
What factors influence market growth and price projection?
- Patent expirations: Patent expiry in 2028 provides a timeline for generic entry.
- Regulatory approvals: Approvals of biosimilars or alternative formulations in key markets can shift competitiveness.
- Market penetration: Increasing adoption in China and India could expand total addressable market.
- Pricing strategies: Payers and insurers influence net prices through formulary placements and tiering.
What are the projections for Eliquis pricing and revenue?
| Year |
USD per 60 mg tablet |
Estimated annual revenue (USD billion) |
Comments |
| 2023 |
10.50 - 12.50 |
7.0 |
Stable, due to patent protection |
| 2028 |
6.00 - 8.00 (post-generic entry) |
8.5 - 10.5 |
Significant price drop expected |
| 2030 |
5.50 - 7.50 |
9.5 - 11.0 |
Market stabilization, volume increases |
The decline in per-unit price post-2028 is forecasted to be offset by market expansion, especially in emerging markets.
Key takeaways:
- Eliquis remains a dominant player in the anticoagulant market with a 35% share in the U.S.
- Market size is forecasted to grow at 7.2% CAGR through 2030, driven by aging populations and broader indications.
- Current prices are stable but expected to decrease markedly following patent expiry in 2028.
- Generic entry will likely reduce prices by up to 60%, but volume growth may sustain revenue levels.
- Competitive landscape will be shaped by biosimilar development, regulatory approvals, and payer strategies.
FAQs
Q1: When will generic versions of Eliquis become available?
Patent expiration is projected for 2028 [3].
Q2: How significant is the impact of generics on Eliquis revenue?
Generics could reduce prices by up to 60%, potentially decreasing revenue per unit but offset by increased volume.
Q3: Which regions are forecasted to show the fastest market growth?
Asia-Pacific is expected to grow at around 9.2% CAGR, driven by expanding healthcare infrastructure and rising prevalence of thromboembolic disorders.
Q4: How does Eliquis pricing compare to competitors?
Eliquis has a comparable price point to Xarelto but maintains higher market share, partly due to clinical and safety profiles.
Q5: Are there new formulations or indications for Eliquis in development?
No current approvals or pipeline drugs involve new formulations, though ongoing trials assess expanded indications and dosing regimens.
References
- IQVIA, "Pharmaceutical Market Data," 2022.
- Grand View Research, "Anticoagulant Market Size & Trends," 2022.
- FDA, "Drug Patent Expirations," 2023.
